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Background: The prevalence of obesity is increasing in industrialized countries. Obesity increases the risk of
coronary artery disease, stroke, cancer, hypertension, and type-2 diabetes. Unfortunately, conventional obesity drug
treatment is often associated with adverse effects. The objective of this study was to evaluate a novel natural
formula, Weight loss herbal intervention therapy (W-LHIT), developed from traditional Chinese medicine, for weight
control in a high-fat-diet (HFD) induced obesity murine model.
Methods: Two sets of experiments were performed. In experiment 1, 14-week-old C57BL/6 J male mice were fed
with HFD for 21days and then separated into 3 weight-matched groups. One group continued on the HFD as
obese-controls. Two groups were switched from HFD to normal fat level diet (NFD) and sham or W-LHIT treated. In
experiment 2, 25-week-old obese mice, following 2weeks acclimatization, received either W-LHIT or sham treatment
while maintained on HFD. In both sets of experiments, NFD fed, age matched normal weight mice served as
normal controls. Body weight and food intake were recorded. Epididymal fat pad weight, serum glucose and
cholesterol levels, as well as PPARγ and FABP4 gene expression in epididymal fat tissue were analyzed at the end
of the experiment.
Results: In experiment 1, W-LHIT treated obese mice lost body weight 12.2 ± 3.8% whereas sham treated mice
lost 5.5 ± 2.8% by day 10 after switching from the HFD to the NFD, without reduction of chow consumption. In
experiment 2, W-LHIT treated obese mice maintained on the HFD had significantly lower body weight (8 fold less)
than the sham treated mice. W-LHIT treatment also reduced epididymal fat pad weight, blood cholesterol and
glucose levels versus sham treated mice without reduced chow consumption. In addition, significantly increased
PPARγ (peroxisome proliferator activated receptor γ) and FABP4 (fatty acid binding protein 4) gene expression were
found in epdidymal fat tissues. Liver and kidney function and hematology testing results of W-LHIT treated mice
were within the normal range.
Conclusions: W-LHIT significantly and safely reduced body weight, normalized glucose and cholesterol levels in
obese mice, without suppression of appetite, and increased adipocyte PPARγ and FABP4 gene expression.
Keywords: Obesity, C57BL/6 J, High fat diet, W-LHIT natural product, Weight loss, Serum glucose, Cholesterol, PPARγ* Correspondence: xiu-min.li@mssm.edu
1Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York,
NY 10029, USA
Full list of author information is available at the end of the article
© 2014 Yang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:261 Page 2 of 12
http://www.biomedcentral.com/1472-6882/14/261Background
In the past 20 years, the worldwide prevalence of obesity
has more than doubled. In 2008, more than 1.4 billion
adults were overweight [1]. Using the definition of obesity
as a body mass index (BMI) greater than or equal to 30,
over 200 million of these men and nearly 300 million of
these women were defined as obese [1]. The National
Health and Nutrition Examination Survey revealed that
more than one-third of adult Americans were obese in
2009–2010 [2]. It is projected that obesity prevalence rates
for the United States will be more than 40% by 2025 [3].
Obesity is a chronic disease associated with significant
morbidity, and has substantial healthcare implications,
due to increased risk for diseases including hypertension,
diabetes, stroke, inflammation disorders and certain can-
cers [3,4]. Overweight and obesity rank as the fifth leading
risk for death globally [1]. At least 2.8 million adults die
each year worldwide as a result of being overweight or
obese [1]. These data demonstrate the major public health
challenge of obesity.
The standard treatment for obesity is diet, exercise and
behavior modification. More than two-thirds of adults in
the United States are either trying to lose weight or to
maintain their weight. However, only 20 percent are both
eating fewer calories and engaging in at least 150 minutes
of physical activity per week [5]. Therefore, lifestyle modi-
fication approaches have had low success rates and
frequent relapses.
Drug therapy has been utilized as an additional treat-
ment component, although issues of efficacy and safety
limit utilization. Current pharmacotherapies include orli-
stat and lorcaserin, as well as a number of sympatho-
mimetic and antiepileptic drugs. The choice of anti-
obesity drugs is often guided by the comorbidities and
relative contraindications of the individual patient. Bariat-
ric surgery is an appropriate option for a specific subset of
patients, although this may result in serious complications.
Due to the possible adverse effects of prescription drugs
for obesity and the potential complications of bariatric
surgery [6], there is increasing interest in herbal medica-
tions for weight loss. Over the counter dietary supple-
ments are widely used by individuals attempting to lose
weight, but evidence supporting their efficacy is lacking.
As reviewed by Manore in 2012 [7], most dietary supple-
ments only result in less than 2 kilogram (2-3%) weight
loss in adults. Certain imported dietary supplements have
been found to be adulterated with prescription drugs, in-
cluding amphetamines, benzodiazepines, and fluoxetine,
which has led to an FDA warning against their use [8].
There still remains a significant gap in the area of safe and
effective weight control products.
Traditional Chinese medicines (TCM) have a long his-
tory of human use in China, Korea, Japan, and other
countries for preventing and treating various diseases aswell as for maintaining weight control. TCM is also begin-
ning to play an important role in the US, along with other
alternative therapies. In the US, TCM is defined as a
“Whole Medical System” by the National Institutes of
Health (NIH) and the National Center of Complementary
and Alternative Medicines (NCCAM) [9]. In 2004, the US
FDA provided guidance for investigating botanical drug
products, including complex formulas containing several
herbs, focusing on safety, efficacy, and consistency. How-
ever, there is no FDA approved oral botanical product
derived from TCM presently available [9]. Given the rep-
utable safety, efficacy and low cost of TCM for weight
control, there is increasing interest in TCM for weight
loss. There has been pioneer research in clinical studies
[10] and animal models [11] to explore the role of TCM
for weight loss. However, experimental evidence based
studies of TCM formulations for weight control following
oral administration have been limited and underlying
mechanisms of TCM for weight control are lacking. In
light of our understanding of metabolic mechanisms
and principles of TCM formulation, we developed weight
loss herbal intervention therapy (W-LHIT), also known as
WL-1. Rodent models of high-fat-diet (HFD) induced
obesity have been well accepted as important research
tools that provide a window into disease pathogenesis and
useful preclinical models for investigation of novel inter-
ventions for obesity treatment [12]. W-LHIT formula
is consist of 6 Chinese herbal medicines, Ganoderma
lucidum (Ling Zhi), rhizome of Coptis chinensis (Huang
Lian), Radix astragali (Huang Qi), Nelumbo nucifera
Gaertn (He Yie), Chaenomeles speciosa (Mu Gua), Fructus
Aurantii (Zhi Qiao). Extract of Nelumbo nucifera seed,
Coptis chinensis, and Fructus auranti have been reported
with anti-obesity effect in animal models [13-15]. Radix
astragali and Ganoderma lucidum reduced the serum
glucose level in diabetic mouse model [16,17]. Chaenomeles
sinensis also showed the antihyerplipidemic, and antihy-
perglycemic effect in diabetic rat. Although, all individ-
ual herbal medicines have been investigated in obesity
related research, they did not present significant weight
loss effect in short period of treatment. The objective of
our study is to investigate W-LHIT formula’s effect in a
HFD-induced obesity murine model. We evaluated the ef-
fect of W-LHIT on body weight, food consumption,
and epididymal fat tissue weight. In addition, we ob-
served the effect on serum glucose, cholesterol, and the




Fourteen-week-old high-fat-diet induced obese and nor-
mal chow fed C57BL/6 J mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). These mice were
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cording to standard guidelines for the care and use of
animals [18]. The study protocol was approved by Insti-
tutional Animal Care and Use Committee at Icahn
Mount Sinai School of Medicine, New York. HFD chow,
prepared by Research Diets, Inc. (New Brunswick, NJ),
was composed of 20 kcal% protein, 35 kcal% carbohy-
drate, and 45 kcal% fat. Normal fat diet (NFD, Purina #
5053, St. Louis, MO), was composed of 23 kcal% protein,
64 kcal% carbohydrate, and 11 kcal% fat.
W-LHIT preparation and quality control
W-LHIT formulation was developed with dried aqueous
extracts of 6 Chinese herbal medicines-Ganoderma
lucidum, rhizome of Coptis chinensis, Radix astragali,
Nelumbo nucifera Gaertn, Chaenomeles speciosa, and
Fructus aurantii. All raw herbs are Chinese origin, which
was certified and individually extracted by a good manufac-
turing product (GMP) facility, Tian Jiang pharmaceutical
Co, Ltd, Jiangsu, China. All herbs were extracted with
water and then concentrated and dried according to the
standard decocting and drying manufacturing process
[19]. The dried powder extract was packaged and stored
at room temperature in a dry and well-ventilated botanical
storage room at Botanical Chemistry Laboratory at Icahn
School of Medicine at Mount Sinai. The tests for heavy
metal and microbial content were conducted by Tianjian
Pharmaceuticoal Ltd. Jiangsu, China and the results met
required standards [20-24].
High pressure liquid chromatography (HPLC) finger-
printing is recommended by the FDA as a means of
standardization of botanical products. The HPLC finger-
print of W-LHIT was generated using a Waters 2690
HPLC coupled with photodiode array detector (PDA;
Waters, Milford, MA). 100 mg of W-LHIT was dissolved
into 1 mL of CH3CN and 0.1% formic acid mixture (1:1 ra-
tio). The solution was filtered through Whatman 0.45 μm
syringe filters (Whatman Inc., Clifton, NJ). 10 μL of filtered
solution was injected and analyzed on a ZORBAX SB-C18
(4.6× 150 mm, 5 μm) column (Agilent, Santa Clara, CA).
0.1% aqueous formic acid was used as mobile phase A
and CH3CN was used as mobile phase B with a constant
flow rate of 1.0 mL/min. The gradient was started at 2% B
and linearly went up to 25% B within 45 min, then to 35%
B within 25 min, to 55% B within 15 min, to 75% B within
10 min, and maintained at 75% B for 5 min. Waters’
Empower software was used for data collection and ana-
lysis. A total of 21 major peaks were present in the HPLC
fingerprint (Figure 1). Twelve compounds were characterized
by Liquid chromatography–mass spectrometry (LC-MS)
as quercetin 3-O-glucuronide from Nelumbo nucifera
Gaertn; hesperidin, nobiletin, tangeretin, and 3-hydroxy-
5,6,7,8,3’,4’-hexamethoxyflavone from Fructus aurantii;
jatrorrhizine, coptisine, and berberine from rhizome ofCoptis chinensis; astragaloside IV from Radix astragali;
ganolucidic acid D, ganoderic acid K, and ganoderic acid
H from Ganoderma lucidum. Their chemical structures
and corresponding peaks are shown in Figure 1. Three
batches of W-LHIT products were generated. HPLC fin-
gerprints of each individual herbal medicine and compari-
son of peak intensities of identified compounds were used
to monitor the quality of different batches of W-LHIT
product. Berberine was used as the key index compound.
W-LHIT treatment
Each mouse received 84 mg W-LHIT daily, dissolved in
1.0 mL drinking water, and intragastrically (i.g.) adminis-
tered by two separate feedings (0.5 mL per feeding
4 hours apart using a standard mouse feeding needle
(VWR, Radnor, PA). The W-LHIT dose was determined
by a conversion table of equivalent human to animal
dose [25]. We employed two protocols in two sets of ex-
periments to determine the effect W-LHIT on weight
control as follows: The first set of experiments was de-
signed to determine the effect of W-LHIT on weight loss
as added-on therapy to dietary calorie reduction on
young mice. In this set of experiments, three groups of
age matched 14 week-old mice (equivalent to human age
of 19 years) were first sham treated by i.g. administration
of water while continuing on the HFD for 3 weeks. This
protocol was used to acclimatize mice to i.g. administra-
tion to prevent potential gavage procedure effect on
weight changes (run-in period). Sham treated normal
weight mice (G4) fed a NFD served as normal controls.
Three weeks later, all mice were weighed. Group 1 obese
mice continued on HFD and sham treatment as the
obesity control group (OB/HFD/Sham). Both group 2
and 3 obese mice were switched from HFD to NFD, but
group 2 mice received W-LHIT (OB/NFD/W-LHIT)
whereas group 3 mice received water sham treatment
(OB/NFD/Sham). Group 4, the normal weight mice,
continued on NFD and water sham treatment to serve
as normal controls (Normal/NFD/Sham). Treatment
duration was 10 days (Figure 2A).
In experiment 2, to determine the effect of W-LHIT on
HFD-induced weight gain in older mice, 14 week-old mice
were maintained in an animal facility at Icahn School of
Medicine at Mount Sinai for 9 weeks on HFD until
23 weeks old (roughly equivalent to 40 human years).
They were then subjected to 2 week acclimatization by i.g.
water administration. These 25 week-old obese mice were
divided into 2 weight matched groups (Figure 3A). Group
1 mice continued on HFD and sham treatment as obese
controls (OB/HFD/Sham) while group 2 mice continued
on HFD and received W-LHIT treatment (OB/HFD/W-
LHIT). Treatment duration was 30 days. Normal weight
mice fed with NFD and water sham treatment were used
as normal controls (Normal/NFD/Sham).
Figure 1 HPLC fingerprint of W-LHIT. HPLC conditions: column, Agilent Zorbax SB-C18 column (150 × 4.6 mm i.d.; 5 μm particle size); flow rate,
1 mL/min; column temperature, 27°C; mobile phase A, 0.1% formic acid, mobile phase B, acetonitrile. Data were processed using Waters Empower
software. Twenty-one major peaks were present in the HPLC fingerprint. Twelve compounds were characterized by LC-MS.
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corded three times a week. Body weight gain was calcu-
lated by subtracting body weight on the first day from
that on the last day of treatment. Daily body weight gain
was calculated by dividing body weight gain by the num-
ber of treatment days. Chow was weighed three times a
week during the period of acclimatization and treatment,
and daily food consumption was calculated by dividing
total food consumption by the number of days.
Biochemical analysis
In experiment 2, mice were fasted overnight after 30 days
of treatment and submandibular blood samples were col-
lected. Sera were separated and stored at −80°C for further
analysis. The mice were sacrificed and tissues were har-
vested, weighed, and stored at −80°C for further analysis.
Serum cholesterol and glucose levels were measured by
ALX Laboratories (New York, NY). Since experiment 1
was a preliminary study designed to determine whether
the effect of W-LHIT as add-on therapy enhances normal
diet intervention weight loss in young obese mice, we didnot pursue biochemistry analysis for serum cholesterol
and glucose levels in experiment 1.
RT-PCR
Epididymal fat pads was collected and weighed from mice
in experiment 2. Total RNA was extracted from epididy-
mal fat tissue using Trizol reagent (Life Technologies,
Grand Island, NY) according to the manufacturer’s instruc-
tions. The concentrations of total RNA were measured
using optical density (OD) readings (Bio-Rad SmartSpect
3000; Bio-Rad, Hercules, CA). cDNA was then synthesized
using ImProm-II™ Reverse Transcriptase Kit (Promega
Corporation, Madison, WI) following the manufacturer’s
instructions. The real time-PCR reaction was performed by
using Maxima™ SYBR Green qPCR Master Mix (2×) kit
(Fermentas, Glen Burnie, MD). PCR was started at 95°C
for 10 minutes followed by 40 cycles. The temperature pro-
file of each cycle was: 95°C for 15 seconds, 60°C for 30 sec-
onds, and 72°C for 30 seconds. The following primers were
used: PPARγ forward: TCGCTGATGCACTGCCTATG;
PPARγ reverse: CGAGTGGTCTTCCATCACGG; FABP4
Figure 2 Effect of W-LHIT on young obese mice bodyweights in experiment 1. A. Protocols of weight loss experiment 1; B. Average
body-weight change curve of sham and W-LHIT treated obese mice over time; C. Daily body weight change; D. Daily food consumption per
mouse; **p < 0.01; ***p < 0.001 (n = 5). Data represent two independent experiments.
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TTCACCTTCCTGTCGTCTGC. Gusb forward: AGTAT
GGAGCAGACGCAATC; Gusb reverse: CTCTCCGACC
ACGTATTCTT. All primers were synthesized by Sigma-
Aldrich Corporation (St. Louis, MO).
Safety testing
For acute toxicity analysis, naive mice were fed with 10
times the daily therapeutic dose for mice of W-LHIT and
observed for 14 days. In the sub-chronic toxicity assay,
naïve mice were fed 5 times their daily therapeutic dose
for 14 days. Sham fed mice served as controls (sham).
Blood samples were collected after each experiment.
Blood urea nitrogen (BUN) and alanine aminotransferase
(ALT) measurements for evaluation of kidney and liver
functions respectively and complete blood count (CBC)
testing were performed by ALX laboratories, NY. Freshly
dissected organs from each mouse were collected and
fixed in 10% formalin. Organs were then dehydrated and
embedded in wax. The sections of different organs were
cut and stained with hematoxylin and eosin (H&E). Theslides were prepared and evaluated by the Pathology ser-
vice, Center for Comparative Medicine and Surgery at
Icahn School of Medicine at Mount Sinai.
Statistical analysis
Data were analyzed using SigmaStat 3.5 software (SPSS
Inc. Chicago, IL). For data that passed normality testing,
differences between groups were analyzed by One Way
Analysis of Variance (One way ANOVA) followed by
pair wise testing using Bonferroni’s adjustment. For data
that appeared skewed (non-normal), differences between
groups were analyzed by One Way ANOVA on Ranks
followed by all pair wise comparisons. P values ≤0.05
were considered significant.
Results
W-LHIT treatment augmented young obese mice weight
loss after switching to a reduced calorie diet
In the first set of experiments, we determined the effect
of combined interventions on young obese mice by
switching from HFD to NFD chow and adding W-LHIT
Figure 3 Effect of W-LHIT on body weights of older obese mice in experiment 2. A. Protocols of weight loss experiment 2; B. Average
body-weight change curve of sham and W-LHIT treated obese mice; C. Daily body weight change before and after treatment; D. Daily food
consumption per mouse; ***p < 0.001(n = 5). Data represent two independent experiments.
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:261 Page 6 of 12
http://www.biomedcentral.com/1472-6882/14/261treatment. During the period of 3-week acclimatization,
all mice on HFD continued to gain essentially the same
amount of body weight (Figure 2B, from days −21 to 0).
During the 10-day treatment period, sham treated obese
mice remaining on HFD continued to gain weight, 6.1 ±
1.0% by day10. However, obese mice switched to NFD
receiving sham treatment (OB/NFD/Sham) lost 2.1 ±
1.4% of body weight by day 3, 3.6 ± 2.5% by day 5, and
5.5 ± 2.8% by day 10. Interestingly, obese mice switched
to NFD who also received W-LHIT treatment lost
weight more rapidly. Mice in this group lost 7.6 ± 1.5%
of their body weight by day 3, 8.7 ± 2.7% by day 6, and
12.2 ± 3.8% by day 10, (Figure 2B). The calculated daily
body weight changes over 10-day treatment period
showed that body weight increased 0.6 ± 0.1% daily in
the OB/HFD/Sham group, but decreased 0.5 ± 0.3%
daily in OB/NFD/Sham group, and decreased 1.2 ± 0.4%
daily in OB/NFD/W-LHIT group. The daily reduction
rate in NFD/W-LHIT mice was 2.4 fold greater than
OB/NFD/Sham mice (p < 0.05) (Figure 2C). Daily chowconsumption did not differ between W-LHIT treated
and Sham treated NFD chow intervention groups
(Figure 2D).
W-LHIT suppressed weight gain in HFD fed older obese mice
In experiment 2, we determined the effect of W-LHIT
on 25 week-old male obese C57BL/6 J mice. After the
run-in period, mice were divided into 2 groups of equal
body weight. Thirty days after initiating treatment, sham
treated mice body weight increased by14.6 ± 2.8% while
on HFD (OB/HFD/Sham). In contrast, W-LHIT treated
obese mice (OB/HFD/W-LHIT) increased body weight
by only 1.9 ± 3.3% (Figure 3B). Daily weight gain in the
OB/HFD/Sham group was 0.49 ± 0.09% whereas daily
weight gain in OB/HFD/W-LHIT group mice was only
0.06 ± 0.10% (Figure 3C, p < 0.001), approximately 8 fold
less than sham treated mice. NFD control mice daily
weight gain was 0.09 ± 0.06% (data not shown). Food in-
take did not differ between W-LHIT treated and sham-
treated mice while on HFD (Figure 3D).
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fed older obese mice
After 30 days on HFD in experiment 2, sham treated
mice had increased body size and more visceral fat
(Figure 4A). W-LHIT treated mice contained less vis-
ceral fat (Figure 4B) and the amount of epididymal adi-
pose tissue was 42% less than that in sham treated mice
(Figure 4C, p < 0.05).
W-LHIT reduced serum cholesterol and glucose levels in
HFD fed older mice
In experiment 2, after 30-day treatment, mice were fasted
overnight, and blood samples were collected. SerumFigure 4 Effect of W-LHIT on epididymal fat tissue weights of older o
W-LHIT treated (right) mice; B. Abdominal fat in Sham (left) and W-LHIT tre
expressed as Mean ± S.D. *p < 0.05 (n = 5).cholesterol and glucose levels were measured. Mice in OB/
HFD/Sham group showed significantly increased serum
total cholesterol levels compared with NFD normal con-
trols (195.0 ± 26.8 vs 93 ± 11 mg/dL, p < 0.01 Figure 5A).
Cholesterol levels in OB/HFD/W-LHIT group (128.5 ±
37.6 mg/dL) were significantly lower than those of sham
treated mice (p < 0.05) and were not statistically different
from the NFD normal controls (Figure 5A).
Blood glucose levels in OB/HFD/W-LHIT mice were
also lower than that in OB/HFD/Sham mice (90.5 ±
39.6 mg/dL vs. 176.0 ± 72.4 mg/dL, p = 0.09), and were not
different from NFD normal mice (121.7 ± 62.2 mg/dL,
p = 0.35) (Figure 5B).bese mice in experiment 2. A. Gross body shape of Sham (left) and
ated (right) mice; C. Epididymal fat per body weight. Data are
Figure 5 Effect of W-LHIT on blood cholesterol and glucose levels of older obese mice in experiment 2. A. Cholesterol levels and B. Glucose
levels in W-LHIT treated and sham-treated older obese mice and normal controls. Data are expressed as Mean ± S.D. *p < 0.05; **p < 0.01 (n≥ 4).
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expression in HFD fed older mice
Total mRNA was extracted from epididymal fat tissues of
sham treated, W-LHIT treated, and normal control mice
in experiment 2, and PPARγ and FABP4 mRNA expression
were analyzed using real time PCR. W-LHIT treatment
significantly increased the expression of PPARγ (p < 0.05,
Figure 6A) and FABP4 (p < 0.05, Figure 6B). We also ana-
lyzed CPT1, UCP2, and AMPK gene expression, which are
related to fat oxidation and metabolism. The results
showed that the relative gene expressions of CTP1, UCP2,
and AMPK in W-LHIT treated mice also trended upward
compared to that in sham treated mice (CTP1, 14.7 ± 12.6
vs. 1.14 ± 0.7; UCP2, 83.8 ± 82.6 vs. 2.2 ± 3.1; and AMPK,
19.1 ± 15.5 vs. 0.2 ± 0.3). However, these increases did not
reach statistical significance.
W-LHIT had a high safety profile
The safety of W-LHIT was tested using 2 protocols. In
an acute toxicity assay, mice were fed ten times the
W-LHIT treatment dose and observed daily for 14 days.
No deaths occurred, and no abnormal behavior or diar-
rhea was observed (Table 1). In a chronic toxicity assay,Figure 6 Real time PCR of epididymal adipose tissues PPARγ (A) and
Mean ± S.D. *p < 0.05 (n≥ 4).mice were fed 5 times the W-LHIT treatment dose for
14 consecutive days. No diarrhea or deaths was ob-
served, and all mice appeared healthy. Mice were then
sacrificed and blood samples were obtained.
Serum ALT and BUN levels were similar to the control
group and within the normal range (Table 1). CBC test-
ing was also performed and white blood cell, red blood
cell, hemoglobin and platelet levels in the treated group
were also within the normal range and similar to the
control group (Table 1). These results demonstrated that
W-LHIT formula has a high safety profile.
Histological sections of the major organs from naïve
mice and W-LHIT treated mice were collected and an-
alyzed (Figure 7). Organs examined include heart, kid-
ney, liver, and spleen. No myocardial vacuolation, no
necrosis, and no inflammation were noted in hearts. No
significant lacy vacuolation and sharply defined vacuol-
ation were observed in liver. No significant difference
of renal tubular proteinosis was observed in kidney.
Very few tubules contain a homogeneous eosinophilic
fluid in kidneys of both naïve and treated mice. No ab-
normalities were observed in spleens in both naïve and
treated mice.FABP4 gene expressions (B) in experiment 2. Data expressed as
Table 1 Safety evaluation of W-LHIT treatment
Treatment Dose Time Death (12 hrs) Death (24 hrs) Morbidity percentage Mortality percentage
Acute Water 10X 1 day 0/5 0/5 0 0
W-LHIT 10X 1 day 0/5 0/5 0 0
Chronic Water 5X 14 days 0/5 0/5 0 0
W-LHIT 5X 14 days 0/5 0/5 0 0


















Water 27.0 ± 2.8 27.5 ± 10.6 6.6 ± 3.1 6.6 ± 3.5 13.7 ± 1.0 1155.0 ± 706.8 2920.5 ± 1247.2 3340.0 ± 2248.2 63.8 ± 82.1 0.0 ± 0.0
W-LHIT 21.0 ± 4.4 33.0 ± 5.4 6.0 ± 3.5 8.1 ± 0.6 12.9 ± 0.8 1056.2 ± 526.3 2233.4 ± 1692.3 3499.2 ± 1763.0 52.0 ± 71.3 0.0 ± 0.0
Reference 14-32 16-58 5.4-16.0 6.7-9.71 10.2-16.6 799-1300 1900-3600 8000-18000 0-500 0-400
























Figure 7 H&E stained sections of major organs of naïve mice
and W-LHIT treated mice.
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Obesity is a growing concern worldwide, and conventional
therapies thus far have proved limited. In this study, we
examined the effects of W-LHIT, a natural product devel-
oped by our laboratory based on TCM, on HFD-induced
obese mice using a previously employed C57BL/6 J mur-
ine model fed a 45% kcal HFD [26]. In the first experi-
ment, mice lost body weight when switched from a HFD
to a NFD. Additionally, W-LHIT formula treatment accel-
erated daily weight loss by 250%. This finding suggests
that, if the same occurred in humans, W-LHIT as part of
a dietary weight loss regimen might help young obese pa-
tients lose weight more quickly.
In the US, the prevalence of obesity in individuals over
40 is much higher than that in younger individuals [2] and
lifestyle changes including dietary modification have been
difficult as a means to stable weight loss for the majority
of middle-aged to senior adults. In a second experiment,
we employed older mice (middle-aged mice) compared
to those in experiment 1 to evaluate if W-LHIT would
also suppress HFD induced weight gain without dietary
intervention. We found that W-LHIT suppressed daily
body weight gain in these mice by approximately 800% ascompared to sham treatment. Consistently, W-LHIT also
reduced epididymal fat weight. If W-LHIT were to have
the same effects in humans, W-LHIT might help limit
weight gain in the absence of appetite suppression medi-
cations and reduced calorie intake interventions. An
additional significant beneficial effect of W-LHIT treat-
ment on HFD fed middle-aged mice was reduction of
blood cholesterol and glucose levels. If the same results
occur in humans, W-LHIT may be valuable in treating pre-
metabolic syndrome and perhaps metabolic syndrome.
Since W-LHIT reduced body weight gain and normal-
ized cholesterol and glucose levels without suppression of
appetite in HFD fed middle-aged mice, we hypothesized
that W-LHIT may affect signaling pathways involved in
cholesterol and glucose metabolism. Fatty-acid-binding
protein (FABP4) is predominantly expressed in adipose
tissue. Recent research found that adipose tissue in obese
individuals exhibited lower FABP4 gene expression than
adipose tissue from lean individuals [27,28]. We found
that adipose tissue FABP4 gene expression was signifi-
cantly increased by W-LHIT treatment. This increased
FABP4 expression might have led to the decreased glucose
levels and body weight. We also measured gene expres-
sion of CPT1, UCP2, which are related to mitochondrial
fatty acid oxidation [29,30], and AMPK, which is import-
ant in energy metabolism [31]. All showed a trend of in-
creased expression levels in the W-LHIT treated group.
Since W-LHIT did not affect food intake, but did signifi-
cantly reduce body weight, accompanied by significant re-
duction of blood cholesterol and glucose levels, we
hypothesize that W-LHIT treatment might induce body
weight loss through regulating the expression of energy
metabolism genes. Previous research showed that activa-
tion of PPARγ is mainly involved in regulating lipid me-
tabolism, insulin sensitivity, and glucose homeostasis and
its agonist has been used in the treatment of hyperlipid-
emia and type 2 diabetes [32]. PPARγ reduces cholesterol
synthesis and is also important in energy metabolism
[33,34]. In animal study, activation of PPARγ increased in-
sulin sensitivity and reduced the glucose levels in circula-
tion and liver through the regulation of the adipocyte-
specific secretory protein, Acrp30 [35]. We found that
PPARγ gene expression was significantly increased in epi-
didymal fat tissue from W-LHIT treated mice compared
to the sham treated mice. This might, at least in part, ex-
plain the decreased glucose and cholesterol serum levels
in this study. In addition to increasing insulin sensitivity
and reducing glucose levels, PPARγ also has a minor
adipogenesis effect [32]. Anti-diabetic Thiazolidinediones
drugs (TZDs), PPARγ agonists, have adipogenic effect as
unwanted effect. Unlike synthetic TZDs, W-LHIT reduced
glucose levels in parallel with the effect of suppression of
body weight and serum cholesterol levels. This beneficial
effect of W-LHIT may attribute to the combination of
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:261 Page 11 of 12
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FABP4, CPT1, UCP2 and AMPK to increase metabolism
and suppress weight gain. This formula may be advanta-
geous to the single molecule drug that targets on single
receptor. Therefore W-LHIT may be a potential as anti-
diabetic TZD complementary therapy to reduce TZD
adverse effect. At present, it is unknown which active
compounds in W-LHIT modulate these gene expressions
or molecular mechanisms underlying this gene regulation,
so further investigation is required.
The safety of all herbs in W-LHIT is well documented
[23,36]. Notably, this formula does not contain the
stimulant Ma Huang (Ephedra sinica), which has signifi-
cant safety concerns when used for weight loss at large
doses [7]. We also conducted standard acute and sub-
chronic toxicity studies in mice. No mortality or morbid-
ity was observed and no abnormal changes, such as
alterations in food and water intake, or diarrhea, were
observed. Biochemical analysis data, hematological data
and histological investigation results also showed that
W-LHIT has a large safety margin.
Conclusion
In conclusion, we present for the first time evidence of the
safety and effectiveness of this Chinese herbal medicine
formula, W-LHIT, in high-fat-diet induced obesity in a
murine model. W-LHIT treatment augmented weight loss
in young obese mice after switching to a reduced calorie
diet. It also prevented weight gain in older mice without
changing the high fat diet. In addition, beneficial effects
were observed on serum cholesterol and glucose levels,
perhaps due to the modulation of expression of energy
metabolism genes such as PPARγ and FABP4. Further
clinical investigation is warranted, as W-LHIT may have
potential for promising human obesity treatment.
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